– NETHERLANDS, Utrecht – LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company today announced the appointments of James Noble and Dr. Jay Backstrom (M.D., M.P.H.) to its Board as Non-Executive Directors.
The Company also announced that Erik van den Berg, Dr. Joël Jean-Mairet, and Dr. Nanna Lüneborg are stepping down from the board following the AGM today.
“We are pleased to welcome James and Jay to LAVA’s board. Their expertise leading clinical development, regulatory affairs, U.S. FDA approvals and finance at global biopharmaceutical companies will be impactful as we advance our two clinical trials for hematologic and metastatic castration-resistant prostate cancers and our earlier stage Gammabody pipeline,” said CEO, Stephen Hurly.
About James Noble
Mr. Noble most recently served as CEO of Adaptimmune Therapeutics plc until 2019 after co-founding it in 2008; he remains on the board. Prior, Mr. Noble was CEO of Immunocore, which he also co-founded. Mr. Noble has also served as a non-executive board director for publicly traded life science companies, including as deputy chairman of GW Pharmaceuticals until its acquisition by Jazz Pharmaceuticals in 2021. Currently, Mr. Noble is chairman of Orexo AB, Sutura Therapeutics, and Celleron Therapeutics.
Mr. Noble received an M.A. from the University of Oxford.
About Dr. Jay Backstrom
Dr. Backstrom most recently served as EVP, research and development, at Acceleron Pharma through its acquisition by Merck in 2021. Previously, Dr. Backstrom was CMO and head of regulatory affairs for Celgene Corporation, where he was instrumental in bringing REBLOZYL®, co-developed by Celgene and Acceleron, through to regulatory approval. Prior, he worked as VP of clinical research and development, myelodysplastic syndrome and acute myeloid leukemia, as well as CMO, through the completion of the Bristol Myers Squibb-Celgene merger in 2019. Dr. Backstrom now serves as a non-executive board director of Autolus Therapeutics, Be Biopharma, and Disc Medicine.
He earned his M.D. and completed medical training at the Lewis Katz School of Medicine at Temple University, and he received a Master’s in public health from the Saint Louis University School of Public Health.
About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company utilizing its proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematological malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer is also enrolling (NCT05369000).
For more information: https://lavatherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.